bioAffinity Technologies (BIAF) versus Its Peers Critical Contrast

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare bioAffinity Technologies to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares bioAffinity Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.55%	-11.34%

Analyst Ratings

This is a breakdown of current ratings for bioAffinity Technologies and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	814	1297	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 9.01%. Given bioAffinity Technologies’ rivals higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its rivals.

Risk & Volatility

bioAffinity Technologies has a beta of 3.93, suggesting that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ rivals have a beta of 6.02, suggesting that their average stock price is 502% more volatile than the S&P 500.

Earnings and Valuation

This table compares bioAffinity Technologies and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-3.07
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	-0.38

bioAffinity Technologies’ rivals have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by company insiders. Comparatively, 16.9% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

bioAffinity Technologies rivals beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.